Topline phase 3 findings show the KIT receptor inhibitor barzolvolimab significantly reduced itch and hives while achieving high complete response rates in patients with chronic spontaneous urticaria.

Investigational therapy ulefnersen demonstrated statistically significant improvements in functional impairment and survival, marking a potential breakthrough for a rare and rapid form of ALS.

No benefit seen in primary end point of median clonal growth rate, but benefits seen in terms of secondary outcomes.

Investigational combination therapy CagriSema demonstrated significant weight reduction and noninferior HbA1c lowering in phase 3 clinical trials.

HealthDay News — High-frequency spinal cord stimulation significantly reduces pain and improves sensory function in people with painful diabetic neuropathy, according to a study published online ...

Probiotic supplement use has surged in the United States, while the consumption of microbiome-supportive foods has remained unchanged, according to a study publ ...

Trimodal therapy can be an alternative to radical cystectomy for select patients with cT2-4aN0M0 muscle-invasive bladder cancer.

HealthDay News — For adults with type 2 diabetes receiving sodium-glucose cotransporter-2 (SGLT2) inhibitors, risk factors for ketoacidosis include high hemoglobin A1c, previous ketoacidosis, and ...

Biweekly enzyme replacement therapy demonstrates efficacy in pediatric and adult hypophosphatasia while offering lower injection frequency.

Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib ...

Phase 3 CELESTIMO study demonstrates significant progression free survival benefit for an mosunetuzumab combination regimen ...

Approval of the nonsteroidal mineralocorticoid receptor antagonist provides the first new treatment option in over 30 years for kidney disease in adults with type 1 diabetes.